NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing, pharma services, and information services. Headquartered in Fort Myers, Florida, the company's core mission is to save lives by improving patient care through exceptional cancer testing, information, and services.

The company offers a comprehensive portfolio of over 500 disease state testing solutions, encompassing various methodologies such as cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC), anatomic pathology, molecular genetics, and next-generation sequencing (NGS). NeoGenomics serves a diverse client base including pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, and managed care organizations across the United States and Europe. Key products include the RaDaR® ST molecular residual disease assay, PanTracer™ LBx liquid biopsy, and PanTracer Pro.

Led by CEO Tony Zook, NeoGenomics reported strong first-quarter 2026 results, with consolidated revenue increasing 11% year-over-year to $187 million, driven by a 14% growth in clinical revenue and 26% growth in NGS. Recent notable developments include the full clinical launch of its RaDaR® ST ctDNA assay, favorable MolDX coverage for PanTracer™ LBx, and the integration of its oncology testing portfolio through Epic Aura to streamline access for healthcare providers. The company maintains a leading position in precision oncology testing, particularly within the community oncology setting.